<DOC>
	<DOCNO>NCT00770029</DOCNO>
	<brief_summary>The study objective show superior efficacy IncobotulinumtoxinA ( Xeomin ) placebo evaluation treatment success analyze investigator 's rating Facial Wrinkle Scale patient 's assessment 4-point scale . 255 female male patient moderate severe glabellar frown line randomize 2:1 ratio receive one injection IncobotulinumtoxinA ( Xeomin ) placebo follow day 120 .</brief_summary>
	<brief_title>IncobotulinumtoxinA ( Xeomin ) Versus Placebo Treatment Glabellar Frown Lines No . 2</brief_title>
	<detailed_description>The study prospective , randomize , double-blind , placebo-controlled , parallel-group , multicenter phase 3 clinical trial . Approximately 285 female male moderate severe glabellar frown line maximum frown screen screening period four month order randomize approximately 255 subject one treatment one placebo group ratio 2 : 1 . After single injection treatment total dose 20 Units IncobotulinumtoxinA ( Xeomin ) correspond placebo , subject observed 120 day . During study participation subject perform seven visit . Eight ( 8 ) site United States Canada participate trial . The study lead one Lead PI Co-Lead PI assist Lead PI . The role Lead PI Co-Lead PI execute one PIs study , respectively . The PI site medical doctor experience aesthetic dermatology , i.e . several year ( &gt; =2 year ) experience treatment glabellar frown line BTX-A preparation . The PI person lead team one trial site responsible conduct clinical trial site . The sub-investigator member team designate PI perform important trial-related decision . A maximum number two sub-investigators could authorize injection rating necessary . At site , ideally one investigator inject rate subject . Injecting rating sub-investigators medical doctor several year experience treatment glabellar frown line BTX-A preparation . A subject rat investigator visit . Another phase 3 trial MRZ 60201-0741/1 ( NCT00770211 ) design endpoints identical trial perform order compare efficacy safety result second study population .</detailed_description>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Age 18 Moderate severe glabellar frown line maximum frown ( severity score 2 3 Facial Wrinkle Scale assess investigator 's rating : 0= 'none ' , 1= 'mild ' , 2= 'moderate ' , 3= 'severe ' Moderate severe glabellar frown line maximum frown ( severity score 2 3 Facial Wrinkle Scale assess patient 's assessment : 0= 'none ' , 1= 'mild ' , 2= 'moderate ' , 3= 'severe ' Stable medical condition Previous treatment Botulinum toxin serotype glabellar area within last 8 month Previous treatment facial aesthetic procedure ( e.g . injection biodegradable filler , chemical peeling , photo rejuvenation ) glabellar area within last 12 month Previous insertion permanent material glabellar area ( regardless time previous treatment study ) Planned treatment Botulinum toxin serotype body region study period Any surgery glabellar area include surgical removal corrugator , procerus , depressor supercilii muscle combination , scar glabellar area surround area ( include eye brow ) Any plan facial aesthetic procedure trial period Inability substantially lessen glabellar frown line even physically spread apart Marked facial asymmetry ptosis eyelid and/or eyebrow History facial nerve palsy Any infection area injection site</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>